Myriad Genetics (MYGN) Change in Acquisitions & Divestments (2009 - 2024)

Myriad Genetics has disclosed Change in Acquisitions & Divestments across 16 years of filings, most recently posting $5.0 million for Q3 2024.

• In Q3 2024, Change in Acquisitions & Divestments fell 66.67% year-over-year to $5.0 million; the TTM figure through Jun 2025 stood at $5.0 million (down 75.61% YoY), while the FY2024 annual figure was $9.0 million, down 91.44% from the prior year.
• Change in Acquisitions & Divestments climbed to $5.0 million in Q3 2024, from $2.5 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for MYGN reached as high as $58.1 million in Q1 2023 and fell as low as $1.5 million in Q4 2023.
• The 5-year median for Change in Acquisitions & Divestments is $18.6 million (2020), against an average of $21.7 million.
• Annual changes were most pronounced in 2020 — Change in Acquisitions & Divestments soared 318.9% — and 2024, when it tumbled 97.42%.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $35.9 million in 2020, then tumbled by 32.31% to $24.3 million in 2021, then surged by 67.08% to $40.6 million in 2022, then sank by 96.31% to $1.5 million in 2023, then surged by 233.33% to $5.0 million in 2024.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $5.0 million, $2.5 million, and $1.5 million for Q3 2024, Q2 2024, and Q1 2024 respectively.